NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NOVAVAX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.82−0.44 (-3.91%)
Close on Oct 19, 2026
- Market cap
- $1.78B
- P/E (TTM)
- –
- Dividend yield
- –
NOVAVAX INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licensing, royalties, and other | $300.10M | $490.78M | $438.44M | $359.56M | $345.54M | $509.92M | $468.96M | $441.85M | $418.70M | $27.98M | $8.49M | – | 72.5% | -13.1% |
| Product sales | $113.69M | $105.56M | $685.04M | $705.09M | $733.18M | $745.04M | $213.20M | $421.90M | $382.61M | $645.18M | $547.89M | $567.72M | 27.5% | -84.5% |
| Supply sales | $84.88M | $78.85M | $59.86M | $49.72M | $39.26M | $29.13M | $22.99M | – | – | – | – | – | 20.5% | +116.2% |
| Nuvaxovid sales | $28.81M | $26.72M | $625.18M | $655.37M | $693.92M | $715.91M | $190.21M | – | – | – | – | – | 7.0% | -95.8% |
| Grants | – | – | – | – | – | – | $0 | $37.94M | $202.87M | $339.94M | $427.32M | $458.95M | – | – |
| Royalties and other | – | – | – | – | – | – | – | – | – | $35.50M | $24.99M | $23.09M | – | – |
| Sales-Based Royalties | – | – | – | – | – | – | – | – | – | – | $8.50M | – | – | – |
| Milestone Payments | – | – | – | – | – | – | – | – | – | – | $0 | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $302.55M | $462.29M | $405.61M | $357.67M | $371.99M | $568.31M | $522.54M | – | – | – | – | – | 73.1% | -18.7% |
| Rest of the world | $85.96M | $106.24M | $126.46M | $112.37M | $110.96M | $93.81M | $59.02M | – | – | – | – | – | 20.8% | -22.5% |
| Europe | $25.29M | $27.80M | $15.74M | $14.48M | $15.64M | $12.72M | $96.14M | – | – | – | – | – | 6.1% | +61.7% |
From the segment and revenue-disaggregation notes of Novavax's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.